Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Fig. 3

Hazard ratios and respective 95% CI for time-to CID by subgroup during 52 weeks of treatment. b.i.d., twice daily; CI, confidence interval; CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IND/GLY, indacaterol/glycopyrronium 110/50 μg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 μg b.i.d

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us